Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 7/20 | 0.46 |
| ▸ | AKT1 | P31749 | 3/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.45 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.45 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.45 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.45 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311020 | 0.80 | HSD11B1 (0.49) | RPS6KB1AKT1 | |
| SCHEMBL310924 | 0.77 | RPS6KB1 (0.59) | RPS6KB1AKT1RPS6KA5RPS6KA4RPS6KA3 | |
| Hydrochloric Acid SCHEMBL312002 | 0.76 | RPS6KB1 (0.60) | RPS6KB1AKT1RPS6KA5RPS6KA4RPS6KA3 | |
| SCHEMBL3317777 | 0.76 | EPHX2 (0.56) | RPS6KB1AKT1EPHX2SOS1ADRB1 | |
| SCHEMBL2928855 | 0.72 | HTR3E (0.55) | EPHX2SOS1ADRB1CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL2276790 | 0.71 | THRB (0.56) | EPHX2SOS1ADRB1CYP1A2CYP2C19 | |
| SCHEMBL192858 | 0.68 | HTR3A (0.43) | ADRB1SIGMAR1 | |
| SCHEMBL14782635 | 0.68 | RPS6KB1 (0.61) | RPS6KB1AKT1RPS6KA5RPS6KA4RPS6KA3 | |
| SCHEMBL1686107 | 0.66 | CYP1A2 (0.50) | EPHX2SOS1ADRB1CYP1A2CYP2C19 | |
| SCHEMBL31030963 | 0.65 | MPL (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| CN-101679439-B | P70S 6 kinase inhibitors | LILLY CO ELI | 2013-09-11 | — | — | CN | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| CN-101679439-A | P70S 6 kinase inhibitors | LILLY CO ELI | 2010-03-24 | — | — | CN | disclosed |
| EP-2148880-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2008140947-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | RPS6KB1 6/4885AKT1 113/4885RPS6KA5 5/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | RPS6KB1 6/4885AKT1 113/4885RPS6KA5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.